指南与共识免疫规划卫生政策与健康促进

高危儿童肺炎球菌疫苗接种建议:全球概览(2022-2024年)

Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).
指南 / 共识 · Vaccine · 2025-09-01

该概览从世界卫生组织、欧洲疾病预防与控制中心门户及各国官方政府与公共卫生网站检索针对高危儿童的肺炎球菌疫苗接种方案。在195个国家中,37.9%(74/195)提供了高危因素儿童疫苗接种政策信息,其中85.1%(63/74)推荐差异化肺炎球菌疫苗接种方案;这些建议在接种程序、风险条件和详细程度上差异很大。

要点

  • 195个国家中37.9%(74/195)有高危儿童肺炎球菌疫苗接种政策信息。
  • 有推荐的国家中85.1%(63/74)推荐差异化肺炎球菌疫苗接种方案。
  • 65.1%(41/63)建议在常规婴儿接种程序后接种1剂或多剂PCV加强针,随后接种PPV23。

核心结论

  • 针对高危因素儿童的肺炎球菌疫苗接种方案相对少见,仅约三分之一国家提供,而常规婴儿接种方案更为广泛采用。
  • 现有高危群体建议因风险条件与接种剂量不同而差异很大。
  • 需要继续制定指南并保障疫苗可及性,以支持为高危因素儿童提供肺炎球菌疫苗接种。

研究设计与样本

  • 从世界卫生组织与欧洲疾病预防与控制中心门户及各国官方政府与公共卫生网站检索针对风险群体的疫苗接种方案。
  • 额外信息直接来自政府来源和该领域专家。
  • 共考虑195个国家。

主要发现

  • 195个国家中37.9%(74/195)提供高危因素儿童疫苗接种政策信息。
  • 有政策信息的国家中85.1%(63/74)推荐差异化肺炎球菌疫苗接种方案。
  • 有推荐的国家中65.1%(41/63)建议在常规婴儿疫苗接种程序后接种1剂或多剂肺炎球菌结合疫苗(PCV)加强针,随后接种23价多糖疫苗(PPV23)。
  • 有推荐的国家中12.7%(8/63)仅推荐后续接种PPV23,20.6%(13/63)仅推荐PCV再接种。
  • PCV13是最常推荐的PCV,更高价次的PCV15和PCV20已被五个国家推荐。

关键数值与推荐

  • 195个国家中37.9%(74/195)提供高危因素儿童疫苗接种政策信息。
  • 有政策信息的国家中85.1%(63/74)推荐差异化肺炎球菌疫苗接种方案。
  • 有推荐的国家中65.1%(41/63)建议常规婴儿程序后接种1剂或多剂PCV加强针,随后接种PPV23。
  • 有推荐的国家中12.7%(8/63)仅推荐后续PPV23,20.6%(13/63)仅推荐PCV再接种。
  • PCV13为最常推荐的PCV,PCV15和PCV20已被五个国家推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal diseases have a major impact on childhood morbidity and mortality across the world. While any child could be infected, those with certain health conditions have an increased risk of infection and subsequent disease severity. This report provides an overview of pneumococcal vaccination policies focused on children considered to be at particular risk of pneumococcal disease. METHODS: Risk-group targeted vaccination schedules were retrieved from the World Health Organization and the European Centre for Disease Prevention and Control portals, and from countries' official governmental and/or public health websites. Additional information was gathered directly from governmental sources and specialists working in the field. RESULTS: Of the 195 countries considered, 37.9% (74/195) provide information on vaccination policies for children with risk factors, with 85.1% of these (63/74) recommending a differentiated pneumococcal vaccination schedule. Among countries with recommendations, 65.1% (41/63) suggest administration of one or more pneumococcal conjugate vaccine (PCV) boosters after the general infant vaccination schedule, followed by the administration of the 23-valent polysaccharide vaccine (PPV23). In contrast, 12.7% of countries (8/63) recommend only subsequent PPV23, whereas 20.6% (13/63) recommend the administration of only PCV revaccination. PCV13 is the most frequently recommended PCV, while the higher-valency PCV15 and PCV20 are already recommended by five countries. Overall, risk-targeted recommendations vary widely according to the vaccination schedule employed, the risk conditions considered, and the level of detail of the recommendations. CONCLUSIONS: Pneumococcal vaccination schedules specifically tailored for children with risk factors are relatively exceptional - present in about one-third of countries - in contrast to the more widely adopted routine infant vaccination schedules. When available, these risk-group recommendations vary widely by conditions and dosing. Continued guidelines development and vaccine access are needed to support the provision of pneumococcal vaccination to children with risk factors.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Daigle D, Morales G, Hayford K, et al. Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024). Vaccine. 2025. PMID: 40896892. doi:10.1016/j.vaccine.2025.127669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。